MedPath

Progesterone

Generic Name
Progesterone
Brand Names
Bijuva, Crinone, Endometrin, Prochieve, Prometrium
Drug Type
Small Molecule
Chemical Formula
C21H30O2
CAS Number
57-83-0
Unique Ingredient Identifier
4G7DS2Q64Y
Background

Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss . Progesterone is used in various contraceptive preparations to prevent ovulation and fertilization , as well as in other formulations to promote and support pregnancy. Please see Medroxyprogesterone acetate, Megestrol acetate, Dydrogesterone and Hydroxyprogesterone entries for information on various other forms of progesterone.

Pharmaceutical progesterone is made from a plant source as a starting material and is chemically identical to progesterone of human ovarian origin . Progesterone is available in gelatinized capsule form, vaginal gel form, tablet form, vaginal insert form, and injection form, all used for various purposes .

Indication

Gelatinized capsules

The gelatinized capsules are indicated for use in the prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea .

Vaginal gel

Progesterone gel (8%) is indicated as progesterone supplementation or replacement as part of an Assisted Reproductive Technology (“ART”) treatment for infertile women with progesterone deficiency. The lower concentration progesterone gel (4%) is used in the treatment of secondary amenorrhea, with the use of the 8% concentration if there is no therapeutic response to the 4% gel .

Vaginal insert

This form is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for infertile women .

Injection (intramuscular)

This drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer .

Tablets, contraceptive

The tablet form of progesterone in contraceptive formulations is indicated for the prevention of pregnancy .

Associated Conditions
Abnormal Uterine Bleeding, Amenorrhea, Endometrial hyperplasia caused by conjugated estrogen, Moderate to Severe Vasomotor Symptoms, Pregnancy, Secondary Amenorrhea, Recurrent spontaneous preterm birth
Associated Therapies
Assisted Reproductive Technology therapy

Effect of Progesterone Administration on Severely Head Injured Patients

Phase 1
Not yet recruiting
Conditions
Severe Head Trauma
Interventions
Drug: The usual head trauma care
First Posted Date
2024-10-08
Last Posted Date
2024-10-08
Lead Sponsor
Assiut University
Target Recruit Count
50
Registration Number
NCT06631547

Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression

Phase 4
Recruiting
Conditions
Major Depressive Disorder
Interventions
Drug: Transdermal placebo patch
Drug: placebo capsule
First Posted Date
2024-09-24
Last Posted Date
2024-09-24
Lead Sponsor
University of North Carolina, Chapel Hill
Target Recruit Count
75
Registration Number
NCT06610305
Locations
🇺🇸

University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States

A Combination of Antibiotics to Decrease Neonatal Morbidity and Mortality for Previable Threatened Labor

Phase 3
Not yet recruiting
Conditions
Previable Labour With Intact Membranes
Interventions
Drug: Combination of antibiotics
Device: Emergency cerclage
First Posted Date
2024-08-27
Last Posted Date
2024-08-27
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
350
Registration Number
NCT06572761
Locations
🇫🇷

Centre Hospitalier Poissy-Saint Germain, Poissy, France

Cerclage with Progesterone Versus Progesterone Only in Singleton Pregnancies

Not Applicable
Recruiting
Conditions
Short Cervix
Preterm Birth
Interventions
Procedure: Cervical cerclage
First Posted Date
2024-06-18
Last Posted Date
2024-09-30
Lead Sponsor
Mỹ Đức Hospital
Target Recruit Count
328
Registration Number
NCT06463652
Locations
🇻🇳

My Duc Hospital, Ho Chi Minh City, Vietnam

To Investigate Efficacy and Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference

Phase 3
Completed
Conditions
Infertility
Interventions
Drug: Placebo GenSci094
Biological: RecFSH / Follitropin alfa (Days 8 to hCG)
Drug: Placebo RecFSH / follitropin alfa
First Posted Date
2023-10-19
Last Posted Date
2024-12-03
Lead Sponsor
Changchun GeneScience Pharmaceutical Co., Ltd.
Target Recruit Count
176
Registration Number
NCT06091436
Locations
🇨🇳

The Sixth Affiliated Hospital, Sun Yat-sen University Guangdong Gastrointestinal Hospital, Guangzhou, Guangdong, China

Vaginal Progesterone Improves Clinical Outcomes of RIF Patients

Not Applicable
Recruiting
Conditions
Infertility, Female
Interventions
First Posted Date
2023-08-22
Last Posted Date
2023-08-22
Lead Sponsor
Nanjing University
Target Recruit Count
152
Registration Number
NCT06005207
Locations
🇨🇳

Reproductive Medicine Center, The affiliated Drum Towel Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China

Adjunctive Vaginal Progesterone in Management of Preterm Labor

Phase 4
Recruiting
Conditions
Preterm Labor
Interventions
First Posted Date
2023-08-18
Last Posted Date
2023-08-30
Lead Sponsor
Chulalongkorn University
Target Recruit Count
48
Registration Number
NCT05997563
Locations
🇹🇭

Vorapong Phupong, Bangkok, Thailand

Effect of Menopause Hormone Therapy In Postmenopausal Women With CSVD And MCI

Phase 2
Not yet recruiting
Conditions
White Matter Hyperintensity
Cerebral Small Vessel Diseases
Mild Cognitive Impairment
Postmenopausal Symptoms
Interventions
First Posted Date
2023-08-08
Last Posted Date
2023-08-08
Lead Sponsor
Beijing Tiantan Hospital
Target Recruit Count
328
Registration Number
NCT05982470
Locations
🇨🇳

Beijing Tiantan Hospital, Beijing, China

Optimal Timing of Euploid Day 6 Blastocyst Transfer in Frozen HRT Cycles, Day 6 or Day 7 of Progesterone Administration.

Phase 1
Recruiting
Conditions
Fertility Issues
Infertility
Infertility, Female
Interventions
Diagnostic Test: Transvaginal ultrasound
Diagnostic Test: Serum LH, E2, P4
Diagnostic Test: Serum P4 day of ET
Procedure: Embryo transfer
First Posted Date
2023-08-07
Last Posted Date
2025-02-21
Lead Sponsor
ART Fertility Clinics LLC
Target Recruit Count
316
Registration Number
NCT05980091
Locations
🇦🇪

ART Fertility Clinics Dubai, Dubai, United Arab Emirates

🇦🇪

ART Fertility Clinics LLC, Abu Dhabi, United Arab Emirates

Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support

Phase 1
Recruiting
Conditions
Pregnancy Related
Infertility, Female
Interventions
Diagnostic Test: Transvaginal ultrasound
Diagnostic Test: Serial serum LH, E2, P4
Diagnostic Test: Serum P4 day of ET - Study Group
Procedure: Embryo transfer
Diagnostic Test: Serum P4 day of ET - Control Group
Diagnostic Test: Serum hCG 10 days after ET
Diagnostic Test: Serum P4 10 days after ET
First Posted Date
2023-08-01
Last Posted Date
2025-01-09
Lead Sponsor
ART Fertility Clinics LLC
Target Recruit Count
342
Registration Number
NCT05969795
Locations
🇦🇪

ART Fertility Clinics Dubai, Dubai, United Arab Emirates

🇦🇪

ART Fertility Clinics LLC, Abu Dhabi, United Arab Emirates

🇦🇪

ART Fertility Clinics Al Ain, Al Ain, United Arab Emirates

© Copyright 2025. All Rights Reserved by MedPath